{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:01:45Z","timestamp":1793822505987,"version":"4.6.1"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.biopha.2023.115513","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T20:28:43Z","timestamp":1695328123000},"page":"115513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing"],"prefix":"10.1016","volume":"167","author":[{"given":"Yushan","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-023-01125-3","article-title":"Tumor immune microenvironment (TIME) to enhance antitumor immunity","volume":"28","author":"Rajbhandary","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.biopha.2023.115513_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-023-02060-3","article-title":"The future of cancer immunotherapy: DNA vaccines leading the way","volume":"40","author":"Pandya","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2023.115513_bib4","article-title":"Advances in landscape and related therapeutic targets of the prostate tumor microenvironment","author":"Li","year":"2023","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"key":"10.1016\/j.biopha.2023.115513_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1135456","article-title":"Cancer immune exclusion: breaking the barricade for a successful immunotherapy","volume":"13","author":"Bruni","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11010055","article-title":"Macrophages as a potential immunotherapeutic target in solid cancers","volume":"11","author":"Mishra","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.115513_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940052","article-title":"Exhaust the exhausters: targeting regulatory T cells in the tumor microenvironment","volume":"13","author":"McRitchie","year":"2022","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2023.115513_bib9","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115513_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.coi.2022.01.001","article-title":"Mechanisms encoding STAT functional diversity for context-specific inflammatory responses","volume":"74","author":"Myers","year":"2022","journal-title":"Curr. Opin. Immunol."},{"issue":"Pt 8","key":"10.1016\/j.biopha.2023.115513_bib11","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2023.115513_bib12","article-title":"Stat3 signaling pathway: a future therapeutic target for bone-related diseases","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115513_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.119006","article-title":"Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: new insight to proliferation and metastasis","volume":"270","author":"Ashrafizadeh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.115513_bib14","article-title":"Pre-clinical investigation of STAT3 pathway in bladder cancer: paving the way for clinical translation","volume":"133","author":"Mirzaei","year":"2021","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12654","article-title":"circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer","volume":"9","author":"Xu","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-00832-w","article-title":"LINC00858 promotes colon cancer progression through activation of STAT3\/5 signaling by recruiting transcription factor RAD21 to upregulate PCNP","volume":"8","author":"Xu","year":"2022","journal-title":"Cell death Discov."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41419-021-03773-x","article-title":"STAT3\/miR-135b\/NF-\u03baB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/jop.12958","article-title":"IL-6 induces haptoglobin expression through activating STAT3 in human head and neck cancer","volume":"49","author":"Li","year":"2020","journal-title":"J. Oral. Pathol. Med.: Off. Publ. Int. Assoc. Oral. Pathol. Am. Acad. Oral. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib20","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180547","article-title":"STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance","volume":"38","author":"Jin","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2023.115513_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jare.2020.07.004","article-title":"Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"26","author":"Lee","year":"2020","journal-title":"J. Adv. Res."},{"issue":"21","key":"10.1016\/j.biopha.2023.115513_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215479","article-title":"Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the STAT3 signaling pathway","volume":"13","author":"Arora","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2023.115513_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091280","article-title":"STAT3, a master regulator of anti-tumor immune response","volume":"11","author":"R\u00e9b\u00e9","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115513_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","article-title":"The role of STAT3 in leading the crosstalk between human cancers and the immune system","volume":"415","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317712445","article-title":"Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment","volume":"39","author":"Liu","year":"2017","journal-title":"Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med."},{"key":"10.1016\/j.biopha.2023.115513_bib26","article-title":"The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy","author":"Garg","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib27","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.22882","article-title":"STAT3 inhibitors for cancer therapy: have all roads been explored","volume":"2","author":"Fagard","year":"2013","journal-title":"Jak. -Stat."},{"issue":"36","key":"10.1016\/j.biopha.2023.115513_bib28","doi-asserted-by":"crossref","first-page":"33576","DOI":"10.1074\/jbc.M104978200","article-title":"Jr.: Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene","volume":"276","author":"Zhang","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.immuni.2012.02.017","article-title":"Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function","volume":"36","author":"Lin","year":"2012","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1073\/pnas.1211805110","article-title":"STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain","volume":"110","author":"Timofeeva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"31","key":"10.1016\/j.biopha.2023.115513_bib31","doi-asserted-by":"crossref","first-page":"29252","DOI":"10.1074\/jbc.M304196200","article-title":"A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation","volume":"278","author":"Ma","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib32","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood.2021015330","article-title":"Aberrant function of pathogenic STAT3 mutant proteins is linked to altered stability of monomers and homodimers","volume":"141","author":"Kasembeli","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111757","article-title":"Structural implications of STAT3 and STAT5 SH2 Domain Mutations","volume":"11","author":"de Araujo","year":"2019","journal-title":"Cancers"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.115513_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(01)02354-7","article-title":"Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation","volume":"495","author":"Schuringa","year":"2001","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41388-020-01566-8","article-title":"STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis","volume":"40","author":"Lin","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s12975-020-00860-7","article-title":"Folic acid deficiency enhances the Tyr705 and Ser727 phosphorylation of mitochondrial STAT3\u00a0in in vivo and in vitro models of ischemic stroke","volume":"12","author":"Dong","year":"2021","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.biopha.2023.115513_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153811","article-title":"Nuclear expression of pSTAT3(Tyr705) and pSTAT3(Ser727) in the stromal compartment of localized hormone-na\u00efve prostate cancer","volume":"232","author":"Marginean","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib38","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.115513_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2023.115513_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cyto.2017.03.018","article-title":"STAT3 in cancer: a double edged sword","volume":"98","author":"Avalle","year":"2017","journal-title":"Cytokine"},{"issue":"27","key":"10.1016\/j.biopha.2023.115513_bib41","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1038\/onc.2014.286","article-title":"Th17-type cytokines, IL-6 and TNF-\u03b1 synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth","volume":"34","author":"De Simone","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CEJ.0b013e3283584932","article-title":"Role of cytokines and Jak3\/Stat3 signaling in the 1,2-dimethylhydrazine dihydrochloride-induced rat model of colon carcinogenesis: early target in the anticancer strategy","volume":"22","author":"Saini","year":"2013","journal-title":"Eur. J. Cancer Prev.: Off. J. Eur. Cancer Prev. Organ."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib43","first-page":"595","article-title":"IL\u201110 secreted by cancer\u2011associated macrophages regulates proliferation and invasion in gastric cancer cells via c\u2011Met\/STAT3 signaling","volume":"42","author":"Chen","year":"2019","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib45","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cmdc.201100194","article-title":"Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules","volume":"6","author":"Fletcher","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2023.115513_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112122","article-title":"Allosteric inhibitors of the STAT3 signaling pathway","volume":"190","author":"Qin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27184-9","article-title":"Interleukin-6\/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells","volume":"8","author":"Gyamfi","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis","volume":"38","author":"Siersb\u00e6k","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib49","first-page":"3351","article-title":"Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma","volume":"62","author":"Masuda","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115513_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18632\/oncotarget.28355","article-title":"Everolimus downregulates STAT3\/HIF-1\u03b1\/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)","volume":"14","author":"Alam","year":"2023","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2023.115513_bib51","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/ijc.23324","article-title":"A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX\/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas","volume":"122","author":"Lee","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cyto.2011.05.012","article-title":"Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry","volume":"55","author":"Piperi","year":"2011","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.20871","article-title":"Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1","volume":"115","author":"Loeffler","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib54","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.31557\/APJCP.2021.22.7.2089","volume":"22","author":"Sanaei","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/2326-6066.CIR-16-0011","article-title":"Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors","volume":"4","author":"Pur\u00e9","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.biopha.2023.115513_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002505","article-title":"Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects","volume":"9","author":"Suarez-Carmona","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030349","article-title":"Mast cell-tumor interactions: molecular mechanisms of recruitment, intratumoral communication and potential therapeutic targets for tumor growth","volume":"11","author":"Segura-Villalobos","year":"2022","journal-title":"Cells"},{"issue":"3\u20131","key":"10.1016\/j.biopha.2023.115513_bib58","article-title":"Roles of phenotypic heterogeneity and microenvironment feedback in early tumor development","volume":"103","author":"Smart","year":"2021","journal-title":"Phys. Rev. E"},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/157488812799859838","article-title":"Microenvironmental regulation of cancer stem cell phenotypes","volume":"7","author":"Quail","year":"2012","journal-title":"Curr. stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003534","article-title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib62","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-21-1978","article-title":"Multi-scale pan-cancer integrative analyses identify the STAT3-VSIR axis as a key immunosuppressive mechanism in head and neck cancer","volume":"28","author":"Katabathula","year":"2022","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115513_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111922","article-title":"Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go","volume":"187","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115513_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.phrs.2019.02.020","article-title":"A TCM formula comprising sophorae flos and lonicerae japonicae flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment","volume":"142","author":"Liu","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216479120","article-title":"ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression","volume":"120","author":"Chuang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"39","key":"10.1016\/j.biopha.2023.115513_bib66","doi-asserted-by":"crossref","first-page":"64505","DOI":"10.18632\/oncotarget.11352","article-title":"Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies","volume":"7","author":"Shou","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib67","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI60083","article-title":"STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Vasquez-Dunddel","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.115513_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-Derived IL-1\u03b2 Drives the IL-6\/STAT3 axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000949","article-title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12013-014-9903-x","article-title":"Targeting IL-10 in auto-immune diseases","volume":"70","author":"Tian","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib71","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jnci\/djz036","article-title":"STAT3 Modulation of Regulatory T cells in response to radiation therapy in head and neck cancer","volume":"111","author":"Oweida","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4110\/in.2010.10.6.219","article-title":"NDRG2-mediated Modulation of SOCS3 and STAT3 activity inhibits IL-10 production","volume":"10","author":"Lee","year":"2010","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2023.115513_bib73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fimmu.2014.00058","article-title":"SOCS3, a Major regulator of infection and inflammation","volume":"5","author":"Carow","year":"2014","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib74","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41419-019-1837-1","article-title":"CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18\/ERK\/STAT3","volume":"10","author":"Han","year":"2019","journal-title":"Cell death Dis."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib75","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib76","first-page":"457","article-title":"Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells","volume":"120","author":"Chalmin","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib77","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1158\/0008-5472.CAN-15-2528","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6\/STAT3 and NO\/NOTCH cross-talk signaling","volume":"76","author":"Peng","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib78","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib79","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7150\/jca.84632","article-title":"Tumor cell-derived extracellular vesicles in modulating phenotypes and immune functions of macrophages: mechanisms and therapeutic applications","volume":"14","author":"Tian","year":"2023","journal-title":"J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib80","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib81","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00262-017-2052-5","article-title":"Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression","volume":"66","author":"Fu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib82","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/0008-5472.CAN-19-2013","article-title":"IL6\/STAT3 Signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung","volume":"80","author":"Jing","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115513_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216205","article-title":"Reprogramming of TAMs via the STAT3\/CD47-SIRP\u03b1 axis promotes acquired resistance to EGFR-TKIs in lung cancer","volume":"564","author":"Lu","year":"2023","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib84","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/MCB.24.4.1453-1463.2004","article-title":"Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression","volume":"24","author":"Jenkins","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2014.07.096","article-title":"IL-27 affects helper T cell responses via regulation of PGE2 production by macrophages","volume":"451","author":"Sato","year":"2014","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2023.115513_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-015-0110-z","article-title":"Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype","volume":"8","author":"Xiao","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib87","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.biopha.2023.115513_bib88","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1245\/s10434-006-9015-y","article-title":"Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice","volume":"13","author":"Viehl","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12122005","article-title":"IGFBP2 drives regulatory T cell differentiation through STAT3\/IDO signaling pathway in pancreatic cancer","volume":"12","author":"Sun","year":"2022","journal-title":"J. Pers. Med."},{"issue":"10","key":"10.1016\/j.biopha.2023.115513_bib90","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","article-title":"Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4\u207a T cells to T-regulatory cells","volume":"71","author":"Olkhanud","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115513_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109048","article-title":"STAT3 inactivation suppresses stemness properties in gastric cancer stem cells and promotes Th17 in Treg\/Th17 balance","volume":"111","author":"Hajimoradi","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib92","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.celrep.2014.02.016","article-title":"S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3","volume":"6","author":"Priceman","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.115513_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2023.115513_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117437","article-title":"PD-L1\/PD-1 axis as a potent therapeutic target in breast cancer","volume":"247","author":"Bastaki","year":"2020","journal-title":"Life Sci."},{"issue":"14","key":"10.1016\/j.biopha.2023.115513_bib95","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.7150\/thno.60040","article-title":"Converged Rab37\/IL-6 trafficking and STAT3\/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment","volume":"11","author":"Kuo","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41368-021-00112-w","article-title":"PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1\/3-EMT signalling","volume":"13","author":"Cui","year":"2021","journal-title":"Int. J. Oral. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib97","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.humimm.2020.02.004","article-title":"The B7-H4 gene induces immune escape partly via upregulating the PD-1\/Stat3 pathway in non-small cell lung cancer","volume":"81","author":"Yuan","year":"2020","journal-title":"Hum. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib98","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.it.2019.06.004","article-title":"Dendritic cell metabolism and function in tumors","volume":"40","author":"Giovanelli","year":"2019","journal-title":"Trends Immunol."},{"issue":"7802","key":"10.1016\/j.biopha.2023.115513_bib99","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.biopha.2023.115513_bib100","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","article-title":"Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells","volume":"70","author":"Herrmann","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib101","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00262-015-1791-4","article-title":"IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells","volume":"65","author":"Ohno","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2023.115513_bib102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lfs.2019.03.009","article-title":"SOCS3 ablation enhances DC-derived Th17 immune response against Candida albicans by activating IL-6\/STAT3 in vitro","volume":"222","author":"Shi","year":"2019","journal-title":"Life Sci."},{"issue":"6181","key":"10.1016\/j.biopha.2023.115513_bib103","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.1251456","article-title":"The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation","volume":"344","author":"Wang","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115513_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00048","article-title":"Long Non-coding RNAs: emerging roles in the immunosuppressive tumor microenvironment","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib105","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3892\/mmr.2014.2510","article-title":"Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development","volume":"10","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"50","key":"10.1016\/j.biopha.2023.115513_bib106","doi-asserted-by":"crossref","first-page":"87244","DOI":"10.18632\/oncotarget.20244","article-title":"CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib108","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/1535-7163.MCT-12-1087","article-title":"Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression","volume":"12","author":"Sun","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib109","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.imbio.2017.05.009","article-title":"STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells","volume":"222","author":"Garrido-Tapia","year":"2017","journal-title":"Immunobiology"},{"issue":"57","key":"10.1016\/j.biopha.2023.115513_bib110","doi-asserted-by":"crossref","first-page":"97516","DOI":"10.18632\/oncotarget.22178","article-title":"Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK\/STAT3 signaling","volume":"8","author":"Kuusanm\u00e4ki","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib111","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.biocel.2013.07.022","article-title":"NBPF is a potential DNA-binding transcription factor that is directly regulated by NF-\u03baB","volume":"45","author":"Zhou","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib112","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.115513_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154319","article-title":"Renal clear cell carcinoma-derived CXCL5 drives tumor-associated fibroblast formation and facilitates cancer progression","volume":"244","author":"Liu","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"14","key":"10.1016\/j.biopha.2023.115513_bib114","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-18-1106","article-title":"Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1","volume":"79","author":"Werfel","year":"2019","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib116","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1158\/2326-6066.CIR-15-0014","article-title":"STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3\/CXCL10 Axis","volume":"3","author":"Yue","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-017-2057-0","article-title":"The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer","volume":"67","author":"Khan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"23","key":"10.1016\/j.biopha.2023.115513_bib118","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/1078-0432.CCR-18-1277","article-title":"STAT3 Inhibition Combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers","volume":"24","author":"Moreira","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2023.115513_bib119","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1158\/0008-5472.CAN-11-1264","article-title":"Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model","volume":"71","author":"Liao","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib120","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1096\/fj.14-257584","article-title":"STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells","volume":"29","author":"Schmetterer","year":"2015","journal-title":"FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.biopha.2023.115513_bib121","article-title":"Quercetin promotes the survival of granulocytic myeloid-derived suppressor cells via the ESR2\/STAT3 signaling pathway","volume":"125","author":"Ma","year":"2020","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115513_bib122","first-page":"41","article-title":"STAT3: a target to enhance antitumor immune response","volume":"344","author":"Lee","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.cji.0000211327.76266.65","article-title":"Stat3 as a potential target for cancer immunotherapy","volume":"30","author":"Kortylewski","year":"2007","journal-title":"J. Immunother."},{"issue":"14","key":"10.1016\/j.biopha.2023.115513_bib124","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/pros.23885","article-title":"The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors","volume":"79","author":"Hellsten","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2023.115513_bib125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcp.2017.08.019","article-title":"A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy","volume":"145","author":"He","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"6 Pt 3","key":"10.1016\/j.biopha.2023.115513_bib126","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.biotechadv.2015.05.010","article-title":"Nanoengineering of vaccines using natural polysaccharides","volume":"33","author":"Cordeiro","year":"2015","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib127","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1165\/rcmb.2012-0387OC","article-title":"Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes","volume":"49","author":"Blank","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115513_bib128","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193220","article-title":"Engineering anti-cancer nanovaccine based on antigen cross-presentation","volume":"39","author":"Warrier","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2023.115513_bib129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semcancer.2020.02.005","article-title":"Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy","volume":"80","author":"Gupta","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib131","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003132","article-title":"Self-assembly nanovaccine containing TLR7\/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib132","article-title":"Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy","volume":"19","author":"Bu","year":"2021","journal-title":"J.\u00a0Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib133","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.6b01119","article-title":"Self-Associating Poly(ethylene oxide)-block-poly(\u03b1-carboxyl-\u03b5-caprolactone) drug conjugates for the delivery of STAT3 inhibitor JSI-124: potential application in cancer immunotherapy","volume":"14","author":"Garg","year":"2017","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201802012","article-title":"Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment","volume":"6","author":"Yang","year":"2019","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202209379","article-title":"A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis","volume":"35","author":"Su","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2023.115513_bib136","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jconrel.2021.03.015","article-title":"Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling","volume":"332","author":"Siv\u00e1k","year":"2021","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201903394","article-title":"Recent progress of potentiating immune checkpoint blockade with external stimuli-an industry perspective","volume":"7","author":"Xu","year":"2020","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2023.115513_bib138","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1302750","article-title":"STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells","volume":"192","author":"Austin","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib139","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1715767","article-title":"Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy","volume":"9","author":"De Martino","year":"2020","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib140","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3892\/or.2014.3479","article-title":"Tunicamycin-induced ER stress regulates chemokine CCL5 expression and secretion via STAT3 followed by decreased transmigration of MCF-7 breast cancer cells","volume":"32","author":"Zhang","year":"2014","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2023.115513_bib141","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-018-4760-8","article-title":"MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis","volume":"170","author":"Dutta","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib142","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00262-020-02701-w","article-title":"Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide","volume":"70","author":"Oweida","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2023.115513_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109110","article-title":"Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8(+) T cell activation to eradicate hepatocellular carcinoma","volume":"112","author":"Cheng","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"39","key":"10.1016\/j.biopha.2023.115513_bib144","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1038\/s41388-018-0340-y","article-title":"Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide","volume":"37","author":"Lu","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2023.115513_bib145","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.18632\/oncotarget.6855","article-title":"STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.biopha.2023.115513_bib146","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-19-4092","article-title":"Radiation with STAT3 blockade triggers dendritic Cell-T cell interactions in the glioma microenvironment and therapeutic efficacy","volume":"26","author":"Ott","year":"2020","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103639","article-title":"Drug repurposing: known knowns to unknown unknowns - network analysis of the repurposome","volume":"28","author":"Cavalla","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib148","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2023.115513_bib149","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.semcancer.2020.04.006","article-title":"Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics","volume":"68","author":"Kirtonia","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib150","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1021\/acs.jcim.3c00282","article-title":"Targeting SARS-CoV-2 main protease: a successful story guided by an in silico drug repurposing approach","volume":"63","author":"Ambrosio","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib151","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-023-05317-w","article-title":"Drug repurposing and prediction of multiple interaction types via graph embedding","volume":"24","author":"Amiri Souri","year":"2023","journal-title":"BMC Bioinforma."},{"issue":"7","key":"10.1016\/j.biopha.2023.115513_bib152","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.7150\/ijbs.81415","article-title":"Drug repurposing flubendazole to suppress tumorigenicity via PCSK9-dependent inhibition and potentiate lenvatinib therapy for hepatocellular carcinoma","volume":"19","author":"Jin","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib153","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2023.115513_bib154","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211027819","article-title":"Metformin antagonizes ovarian cancer cells malignancy through Msln mediated IL-6\/STAT3 signaling","volume":"30","author":"Yang","year":"2021","journal-title":"Cell Transplant."},{"issue":"19","key":"10.1016\/j.biopha.2023.115513_bib155","doi-asserted-by":"crossref","first-page":"28235","DOI":"10.18632\/oncotarget.8595","article-title":"Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2\/PGE2\/STAT3 axis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.115513_bib156","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2016.12.031","article-title":"Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2\/PGE2\/STAT3 axis","volume":"389","author":"Tong","year":"2017","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.biopha.2023.115513_bib157","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.417","article-title":"Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-\u03b21\/STAT3 axis-regulated EMT","volume":"8","author":"Liu","year":"2017","journal-title":"Cell death Dis."},{"issue":"15","key":"10.1016\/j.biopha.2023.115513_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158083","article-title":"Metformin enhances the anti-cancer efficacy of sorafenib via suppressing MAPK\/ERK\/Stat3 axis in hepatocellular carcinoma","volume":"23","author":"Siddharth","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170318","article-title":"High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer","volume":"12","author":"Wallbillich","year":"2017","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib160","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5945-1","article-title":"Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3\/NF-\u03baB pathways","volume":"19","author":"Esparza-L\u00f3pez","year":"2019","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2023.115513_bib161","doi-asserted-by":"crossref","first-page":"34832","DOI":"10.18632\/oncotarget.8989","article-title":"Metformin blocks progression of obesity-activated thyroid cancer in a mouse model","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib162","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/s41388-021-01682-z","article-title":"Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2\/STAT3\/SOX2 signaling","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2023.115513_bib163","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10863-018-9755-y","article-title":"Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer","volume":"50","author":"Lv","year":"2018","journal-title":"J. Bioenerg. Biomembr."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib164","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10637-019-00790-8","article-title":"Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK\/STAT3 signaling","volume":"38","author":"Zhang","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2023.115513_bib165","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.7150\/ijbs.63125","article-title":"Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer","volume":"17","author":"Lin","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2023.115513_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118522","article-title":"Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer","volume":"262","author":"Wu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.115513_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.012","article-title":"Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway","volume":"169","author":"Zhu","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115513_bib168","article-title":"Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest","volume":"13","author":"V\u00edtovcov\u00e1","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115513_bib169","doi-asserted-by":"crossref","DOI":"10.1007\/s13402-023-00822-9","article-title":"Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6\/STAT3 pathway","author":"Ji","year":"2023","journal-title":"Cell. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.115513_bib170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11010-017-3084-z","article-title":"Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug","volume":"436","author":"Sau","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.biopha.2023.115513_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092141","article-title":"Pimozide suppresses the growth of brain tumors by targeting STAT3-mediated autophagy","volume":"9","author":"Ranjan","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.biopha.2023.115513_bib172","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/omi.2019.0151","article-title":"Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics","volume":"23","author":"Koromina","year":"2019","journal-title":"A. J. Integr. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115513_bib173","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12551","article-title":"An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy","volume":"28","author":"Querol","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"5","key":"10.1016\/j.biopha.2023.115513_bib174","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006290","article-title":"Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies","volume":"11","author":"Magr\u00e9","year":"2023","journal-title":"J. Immunother. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223013112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223013112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:39:22Z","timestamp":1776461962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223013112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":174,"alternative-id":["S0753332223013112"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115513","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115513"}}